JP2004535430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004535430A5 JP2004535430A5 JP2003506572A JP2003506572A JP2004535430A5 JP 2004535430 A5 JP2004535430 A5 JP 2004535430A5 JP 2003506572 A JP2003506572 A JP 2003506572A JP 2003506572 A JP2003506572 A JP 2003506572A JP 2004535430 A5 JP2004535430 A5 JP 2004535430A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- modified pectin
- medicament
- patient
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001277 pectin Polymers 0.000 description 9
- 235000010987 pectin Nutrition 0.000 description 9
- 239000001814 pectin Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 102000007563 Galectins Human genes 0.000 description 2
- 108010046569 Galectins Proteins 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical class OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 102000000795 Galectin 1 Human genes 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102000000802 Galectin 3 Human genes 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29999101P | 2001-06-21 | 2001-06-21 | |
| US10/176,235 US6680306B2 (en) | 2001-06-21 | 2002-06-20 | Method for enhancing the effectiveness of cancer therapies |
| PCT/US2002/019885 WO2003000118A2 (en) | 2001-06-21 | 2002-06-21 | Method for enhancing the effectiveness of cancer therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004535430A JP2004535430A (ja) | 2004-11-25 |
| JP2004535430A5 true JP2004535430A5 (enExample) | 2006-01-05 |
Family
ID=26872020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506572A Pending JP2004535430A (ja) | 2001-06-21 | 2002-06-21 | 癌治療の有効性を向上させる方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6680306B2 (enExample) |
| EP (1) | EP1406639A4 (enExample) |
| JP (1) | JP2004535430A (enExample) |
| CN (1) | CN100558367C (enExample) |
| AU (1) | AU2002320140B2 (enExample) |
| BR (1) | BR0210550A (enExample) |
| CA (1) | CA2451841A1 (enExample) |
| CZ (1) | CZ200487A3 (enExample) |
| IL (1) | IL159461A0 (enExample) |
| MX (1) | MXPA03012021A (enExample) |
| WO (1) | WO2003000118A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2440555A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| US20030004132A1 (en) * | 2001-06-22 | 2003-01-02 | Yan Chang | Method and material for treating immune diseases |
| US6890906B2 (en) | 2001-11-21 | 2005-05-10 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| US20040121981A1 (en) * | 2001-11-21 | 2004-06-24 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| US20040259816A1 (en) * | 2002-10-01 | 2004-12-23 | Pandol Stephen J. | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
| AU2004229399B2 (en) * | 2003-04-07 | 2010-08-05 | Prospect Therapeutics, Inc. | Composition and uses of galectin antagonists |
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| WO2005007110A2 (en) * | 2003-07-11 | 2005-01-27 | Pro-Pharmaceuticals, Inc. | Compositions and methods for hydrophobic drug delivery |
| DE10335236B3 (de) * | 2003-08-01 | 2005-02-24 | Drägerwerk AG | Messsystem für die Bestimmung der Konzentration von Propofol (2,6-Diisopropylphenol) im Atemstrom |
| US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| US20050282773A1 (en) * | 2004-01-14 | 2005-12-22 | Pro-Pharmaceuticals, Inc. | Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer |
| EP1718146A2 (en) * | 2004-02-13 | 2006-11-08 | Pro-Pharmaceuticals, Inc. | Compositions and methods used to treat acne and candida |
| CA2582428A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
| WO2006020027A1 (en) * | 2004-07-14 | 2006-02-23 | Glycogenesys, Inc. | Composition and method for treating hyperproliferative diseases |
| EP1773128A2 (en) * | 2004-08-02 | 2007-04-18 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins |
| BRPI0607579A2 (pt) * | 2005-03-23 | 2009-09-15 | Pfizer Prod Inc | uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncer |
| US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
| US7919250B2 (en) * | 2007-07-31 | 2011-04-05 | New York University | Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions |
| CA2778953C (en) | 2009-11-13 | 2020-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
| EP2788761B1 (en) * | 2011-12-08 | 2018-02-28 | Eliaz Therapeutics, Inc. | Reduction of galectin-3 levels by plasmapheresis |
| KR101968370B1 (ko) * | 2011-12-28 | 2019-04-11 | 갈렉틴 테라퓨틱스, 인크. | 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물 |
| WO2013152313A1 (en) * | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| ES2848538T3 (es) | 2012-06-06 | 2021-08-10 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible |
| BR112015005772A2 (pt) | 2012-09-17 | 2017-08-08 | Galectin Therapeutics Inc | método para a intensificação de imunoterapias específicas no tratamento de câncer |
| JP6055928B2 (ja) | 2012-10-10 | 2016-12-27 | ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物 |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
| CA2930817A1 (en) | 2013-11-17 | 2015-05-21 | Rdd Pharma Ltd. | Methods for treating radiation induced gastrointestinal tract injury |
| CA3031691A1 (en) * | 2016-09-13 | 2018-03-22 | Rasna Research Inc. | Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US107222A (en) * | 1870-09-13 | Improvement in machines for tenoning window-sash | ||
| US5490991A (en) | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
| US5843442A (en) | 1990-10-22 | 1998-12-01 | Corvas International, Inc. | Blood coagulation protein antagonists and uses therefor |
| US5639737A (en) | 1991-11-04 | 1997-06-17 | Co Enzyme Technology Ltd. | Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors |
| US20020107222A1 (en) | 1993-03-01 | 2002-08-08 | David Platt | Modified polysaccharides for treatment of cancer |
| US5490911A (en) * | 1993-11-26 | 1996-02-13 | The United States Of America As Represented By The Department Of Energy | Reactive multilayer synthesis of hard ceramic foils and films |
| US5498702A (en) * | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
| US5834442A (en) * | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
| US5681923A (en) | 1995-10-06 | 1997-10-28 | Platt; David | Tumor derived carbohydrate binding protein |
| KR19990087665A (ko) * | 1996-03-15 | 1999-12-27 | 오미야 히사시 | 우론산의 가열-처리 산물, 이를 함유하는 식품, 음료 또는 약제 |
| US5831052A (en) * | 1997-05-07 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | New human translocation associated protein |
| EP1391206B1 (en) * | 1997-10-15 | 2008-07-02 | Polarx Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma |
| US6258383B1 (en) * | 1998-08-14 | 2001-07-10 | Lactoferrin Products Company | Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format |
| US6500807B1 (en) * | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
| US6274566B1 (en) * | 1999-02-23 | 2001-08-14 | Econugenics, Inc. | Methods for treating mammals with modified alginates and pectins |
| WO2002026262A2 (en) | 2000-09-25 | 2002-04-04 | Pro-Pharmaceuticals, Inc. | Compositions for reducing side effects in chemotherapeutic treatments |
| US20020104222A1 (en) * | 2001-02-06 | 2002-08-08 | Jay Larry Dean | Knife for removing the hide of an animal and method therefor |
| US6914055B2 (en) * | 2001-03-27 | 2005-07-05 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| US6645946B1 (en) * | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| US6982255B2 (en) * | 2001-03-27 | 2006-01-03 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| WO2002076474A1 (en) | 2001-03-27 | 2002-10-03 | Pro-Pharmaceuticals, Inc. | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| WO2006020027A1 (en) * | 2004-07-14 | 2006-02-23 | Glycogenesys, Inc. | Composition and method for treating hyperproliferative diseases |
-
2002
- 2002-06-20 US US10/176,235 patent/US6680306B2/en not_active Expired - Fee Related
- 2002-06-21 BR BR0210550-0A patent/BR0210550A/pt not_active IP Right Cessation
- 2002-06-21 CN CNB028160037A patent/CN100558367C/zh not_active Expired - Fee Related
- 2002-06-21 JP JP2003506572A patent/JP2004535430A/ja active Pending
- 2002-06-21 WO PCT/US2002/019885 patent/WO2003000118A2/en not_active Ceased
- 2002-06-21 EP EP02749641A patent/EP1406639A4/en not_active Withdrawn
- 2002-06-21 MX MXPA03012021A patent/MXPA03012021A/es not_active Application Discontinuation
- 2002-06-21 IL IL15946102A patent/IL159461A0/xx unknown
- 2002-06-21 AU AU2002320140A patent/AU2002320140B2/en not_active Ceased
- 2002-06-21 CZ CZ200487A patent/CZ200487A3/cs unknown
- 2002-06-21 CA CA002451841A patent/CA2451841A1/en not_active Abandoned
-
2003
- 2003-04-07 US US10/408,723 patent/US20040023925A1/en not_active Abandoned
- 2003-09-08 US US10/657,383 patent/US20040043962A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004535430A5 (enExample) | ||
| CN102114031B (zh) | 使用于炎症性肠疾病治疗和预防的透明质酸混合物 | |
| US8735373B2 (en) | Glycosaminoglycan oral use and compositions | |
| PL2099462T3 (pl) | Preparat farmaceutyczny do leczenia schorzeń zapalnych przewodu moczowo-płciowego | |
| CA2337152C (en) | Pharmaceutical composition intended in particular for the prevention and the treatment of radiomucositis and chemomucositis | |
| WO2002049501A3 (en) | Local regional chemotherapy and radiotherapy using in situ hydrogel | |
| CA2590159A1 (en) | Regimens for intra-articular viscosupplementation | |
| JP2003522796A5 (enExample) | ||
| WO2019155389A1 (en) | An aqueous mucoadhesive and bioadhesive composition for the treatment | |
| WO2009093264A3 (en) | Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. | |
| CN104027448A (zh) | 一种壳聚糖凝胶及其制备方法 | |
| ITMI20130075A1 (it) | Combinazione orale per la prevenzione e il trattamento di patologie vescicali, pelviche e dell¿apparato uro-genitale | |
| US20080182816A1 (en) | Methods for preparing a novel family of polysaccharride prodrugs for colonic delivery | |
| JP2011037849A (ja) | 消化性潰瘍及び十二指腸潰瘍の治療及び予防に使用されるヒアルロン酸混合物 | |
| JP2006516571A5 (enExample) | ||
| JP2004536825A5 (enExample) | ||
| WO2005025501A3 (en) | Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer | |
| TWI516269B (zh) | 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物 | |
| US9241953B2 (en) | Glycosaminoglycan oral use and compositions | |
| CA2519797A1 (en) | Low molecular weight hyaluronic acid for the treatment of nerve damage | |
| EP0392888B1 (fr) | Compositions thérapeutiques pour le traitement ou la prévention du ronflement | |
| TW201124142A (en) | Hypersulfated disaccharide formulations | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| CN118019520A (zh) | 分离的多糖化合物及其使用和制备的方法 | |
| Singh et al. | Chitosan hydrogel: Its applications in medicine and dentistry |